Therapeutic
class |
Drugs |
Lipid modifying effects |
Initial
dose |
Side effect |
Contraindication |
|
LDL |
HDL |
TG |
HMG-CoA
reductase
inhibitors |
Atorvastatin |
$
25-40% |
#
5-10% |
$$ |
10 mg once |
Myopathy,
increased liver enzymes |
Active
or chronic liver diseae, pregnancy & lactation |
| Simvastatin |
$
25-40% |
#
5-10% |
$$ |
5 mg once |
| Lovastatin |
$
25-40% |
#
5-10% |
$$ |
10 mg once |
| Fluvastatin |
$
20-30% |
#
5-10% |
$$ |
20 mg once |
| Parvastatin |
$
25-40% |
#
5-10% |
$$ |
20 mg once |
| Fibric acids (Fibrates) |
Gemifibrozil |
$
10-15% |
#
15-20% |
$$ |
600 mg once |
Dyspepsia, Myopathy |
Severe Renal &
hepatic disease |
| Nicotinic acid |
Niacin |
$
15-25% |
#
25-35% |
$$ |
100 mg once |
Flushing,
hyperglycemia, hyperuricemia, hepatotoxisity |
Chronic liver
disease, severe gout, diabetes, peptic ulcer disease |
| Bile
acid sequestrants |
Cholestyramine |
$
15-25% |
#
5% |
|
4 g bd |
Gastro
intestinal distress, constipation |
Dysbetalipop-rotienemia TG > 400 mg/dl |
| Colestipol |
$
15-25% |
#
5% |
|
5 g bd |
| Cholesterol
absorption inhibitors |
Ezetimibe |
$
10-20% |
minimal
change |
|
10 mg once |
Headache, Angioedema |
Hypersensitivity |
|
Chapter 28: Lipid
abnormality; CMDT 2004 |
|
Table 11: Drug
therapy for dyslipidemia |
